Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - isosorbide mononitrate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - tamoxifen citrate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate; naproxen -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - lisinopril -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; povidone; magnesium stearate - indications as at 23 november 2004 : oral therapy - hypertension, angina pectoris prophylaxis, suspected or definite myocardial infarction, migraine prophylaxis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metoprolol tartrate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - indications as at 23 nov 2004 : intravenous therapy - disturbances of cardiac rhythm , in particular supraventricular tachyarrhythmias.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; crospovidone; purified talc; iron oxide yellow; sodium stearylfumarate; synthetic paraffin; methacrylic acid copolymer; hypromellose; hyprolose; triethyl citrate; iron oxide red; magnesium stearate; polysorbate 80; glyceryl monostearate; titanium dioxide; macrogol 6000; maize starch; sucrose - healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - dapagliflozin propanediol monohydrate, quantity: 12.3 mg (equivalent: dapagliflozin, qty 10 mg); saxagliptin, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose; croscarmellose sodium; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid - qtern 5/10 is indicated as an adjunct to diet and exercise, in combination with metformin, to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and dapagliflozin is appropriate.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - osimertinib mesilate, quantity: 47.7 mg (equivalent: osimertinib, qty 40 mg) - tablet, film coated - excipient ingredients: purified talc; polyvinyl alcohol; hyprolose; iron oxide black; mannitol; titanium dioxide; macrogol 3350; sodium stearylfumarate; iron oxide red; iron oxide yellow; microcrystalline cellulose; purified water - tagrisso is indicated:,? as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (nsclc) whose tumours have activating epidermal growth factor receptor (egfr) mutations, as detected by a validated test.,? for the first-line treatment of patients with locally advanced or metastatic nsclc whose tumours have activating egfr mutations, as detected by a validated test.,? for the treatment of patients with locally advanced or metastatic nsclc that is egfr t790m mutation-positive, as detected by a validated test.